Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can better surveillance of hepatitis b and d prevent liver damage?

NCT ID NCT07727187

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This observational study follows adults in France who are newly diagnosed with chronic hepatitis B (with or without hepatitis D). Researchers will measure liver scarring, treatment eligibility, and viral characteristics to understand how severe the disease is at diagnosis. The goal is to improve screening and care strategies to meet global targets for reducing hepatitis-related deaths.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
This study could help improve screening and care for hepatitis B and D, potentially reducing liver-related deaths in France.
What could go wrong
As an observational study, it does not test a new treatment, so it will not directly change outcomes for participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,360 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with chronic hepatitis B surface antigen (HBsAg) carriage, defined as persistent HBsAg positivity for at least 6 months or HBsAg positivity in the absence of anti-HBc IgM antibodies.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Chronic HBsAg carriage * First referral to participating expert/reference hepatology centers or hepatology/infectious diseases departments * Written informed consent obtained * Affiliation with national health insurance system or equivalent coverage Exclusion Criteria: * Telephone-only referrals or medical record-only consultations * Telemedicine-only consultations * Inability or unwillingness to comply with study procedures * Inability to understand study objectives or procedures * Individuals deprived of liberty, under guardianship or under conservatorship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic hepatitis B infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection cirrhosis of liver hepatitis B virus infection hepatitis D virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic hepatitis B infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Stéphane Chevaliez

    Créteil, 9400, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.